AbbVie Loses Judge-Switch Bid In Humira Kickback Battles
Law360 (March 18, 2021, 10:12 PM EDT) -- AbbVie Inc. lost a bid on Thursday to have a single judge handle a pair of closely watched fraud cases over allegations that the company illegally marketed its drug Humira, with an Illinois federal judge ruling that reassignment would significantly delay a whistleblower's False Claims Act case before her.
U.S. District Judge Rebecca R. Pallmeyer rejected AbbVie's request to reassign to her court a proposed securities class action currently before U.S. District Judge Charles Ronald Norgle Sr. Both cases are in the Northern District of Illinois and deal with allegations that the company used unlawful kickbacks to market Humira.
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!